Regen firm Mesoblast to expand beyond ortho with Angioblast buy
This article was originally published in Clinica
Executive Summary
Regenerative medicine firm Mesoblast is to grow its business beyond the treatment of orthopaedic disorders by acquiring stem cell technology expert Angioblast systems in a stock-for-stock deal.